1. Home
  2. IVVD vs DLHC Comparison

IVVD vs DLHC Comparison

Compare IVVD & DLHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IVVD
  • DLHC
  • Stock Information
  • Founded
  • IVVD 2020
  • DLHC 1969
  • Country
  • IVVD United States
  • DLHC United States
  • Employees
  • IVVD N/A
  • DLHC N/A
  • Industry
  • IVVD Biotechnology: Pharmaceutical Preparations
  • DLHC Business Services
  • Sector
  • IVVD Health Care
  • DLHC Consumer Discretionary
  • Exchange
  • IVVD Nasdaq
  • DLHC Nasdaq
  • Market Cap
  • IVVD 96.7M
  • DLHC 79.6M
  • IPO Year
  • IVVD 2021
  • DLHC N/A
  • Fundamental
  • Price
  • IVVD $0.73
  • DLHC $5.52
  • Analyst Decision
  • IVVD Strong Buy
  • DLHC
  • Analyst Count
  • IVVD 3
  • DLHC 0
  • Target Price
  • IVVD $5.85
  • DLHC N/A
  • AVG Volume (30 Days)
  • IVVD 653.6K
  • DLHC 22.6K
  • Earning Date
  • IVVD 08-13-2025
  • DLHC 08-06-2025
  • Dividend Yield
  • IVVD N/A
  • DLHC N/A
  • EPS Growth
  • IVVD N/A
  • DLHC 75.08
  • EPS
  • IVVD N/A
  • DLHC 0.38
  • Revenue
  • IVVD $36,688,000.00
  • DLHC $377,074,000.00
  • Revenue This Year
  • IVVD $345.16
  • DLHC N/A
  • Revenue Next Year
  • IVVD $161.08
  • DLHC N/A
  • P/E Ratio
  • IVVD N/A
  • DLHC $15.01
  • Revenue Growth
  • IVVD N/A
  • DLHC N/A
  • 52 Week Low
  • IVVD $0.35
  • DLHC $2.72
  • 52 Week High
  • IVVD $2.74
  • DLHC $11.42
  • Technical
  • Relative Strength Index (RSI)
  • IVVD 46.86
  • DLHC 45.31
  • Support Level
  • IVVD $0.68
  • DLHC $5.68
  • Resistance Level
  • IVVD $0.86
  • DLHC $5.92
  • Average True Range (ATR)
  • IVVD 0.05
  • DLHC 0.18
  • MACD
  • IVVD -0.00
  • DLHC -0.04
  • Stochastic Oscillator
  • IVVD 36.09
  • DLHC 4.44

About IVVD Invivyd Inc.

Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.

About DLHC DLH Holdings Corp.

DLH Holdings Corp is a provider of technology-enabled business process outsourcing and program management solutions in the United States. The company offers services to several government agencies which include the Department of Veteran Affairs. The company is engaged in public health, performance evaluation, and health operations to solve the complex problems faced by civilian and military customers alike, leveraging digital transformation, artificial intelligence, analytics, cloud-based applications, telehealth systems, and others.

Share on Social Networks: